Nicky Cooper
CEO
River BioMedics
This company develops novel therapies for cardiovascular diseases by focusing on direct targeting of the heart muscle. They utilize expertise in bio-engineering and human induced pluripotent stem cells (hiPSC) to create advanced 3D cardiac in vitro models. These models support the discovery and development pipeline for new cardiac drugs.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$4.3MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional methods of pre-clinical cardiac drug testing often fail to accurately predict drug responses in humans, leading to costly late-stage failures in clinical trials. Existing 2D cell cultures and animal models do not fully replicate the complex 3D structure and function of the human heart, resulting in inaccurate assessments of drug efficacy and toxicity.
Solution
River BioMedics develops advanced 3D in vitro human cardiac models utilizing human induced pluripotent stem cells (hiPSC) to provide more predictive and clinically relevant platforms for cardiac drug discovery. Their portfolio includes a 3D Cardiac Strip, Heart-on-a-Chip, and Mini-Heart, each designed to mimic the structure and function of the human heart muscle. These models enable researchers to directly target the heart muscle and obtain detailed, clinically relevant read-outs, enhancing the efficiency of therapeutic development for cardiovascular diseases. River BioMedics' technology aims to bridge the gap between pre-clinical testing and clinical outcomes, reducing the risk of late-stage drug failures.
Target Audience
The primary customers are pharmaceutical companies, biotech firms, and academic research institutions involved in cardiac drug discovery and development.
Features
- 3D Cardiac Strip: A multicellular cardiac tissue construct for evaluating contractile force and electrophysiological activity.
- Heart-on-a-Chip: A microfluidic device that replicates the physiological microenvironment of the human heart, enabling real-time monitoring of cardiac function.
- Mini-Heart: A miniaturized 3D cardiac model that mimics the structural and functional properties of the human heart, suitable for high-throughput screening.
- hiPSC-derived cardiomyocytes: Models are created using human induced pluripotent stem cells, ensuring human-relevant cardiac tissue.
- Clinically relevant read-outs: Provides detailed data on cardiac function, including contractility, electrophysiology, and calcium handling.
- High-throughput screening: Enables efficient screening of drug candidates, accelerating the drug discovery process.